Bibliographic record
Abstract
Canada’s Drug Agency (CDA-AMC) recommends that Vanflyta should be reimbursed by public drug plans for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) with an FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation if certain conditions are met. Vanflyta, in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy followed by maintenance monotherapy with Vanflyta, should only be covered to treat patients with newly diagnosed primary AML or AML secondary to myelodysplastic syndrome or a myeloproliferative neoplasm, and with good performance status. The presence of an FLT3-ITD–activating mutation in bone marrow should be identified using a validated test. Vanflyta should only be reimbursed if treatment is initiated by clinicians with expertise in managing AML in institutions with expertise in systemic therapy delivery. Vanflyta should be negotiated so that the total treatment cost does not exceed the drug program cost of treatment with midostaurin reimbursed for the treatment of adult patients with newly diagnosed AML that is FLT3-ITD positive.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.001 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.020 | 0.006 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".